전 슬관절 치환술 후 오피오이드 대안으로서의 NEUROCUPLE™
전 슬관절 치환술 환자에게 오피오이드 대안으로서 NEUROCUPLE™의 역할
The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.
The main questions it aims to answer are:
- Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?
- Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?
Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.
Participants will:
- Apply the NEUROCUPLE device or placebo device for 7 days following surgery
- Have their pain and opioid use monitored through clinical records and patient reporting
- Report pain at rest and during movement on postoperative Days 2 and 7
- Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jacques E. Chelly, MD, PhD, MBA
- 전화번호: (412)623-6904
- 이메일: ChelJE@anes.upmc.edu
연구 연락처 백업
- 이름: Heather Margonari, DNP, FNP, BC
- 전화번호: 412-623-1914
- 이메일: margonarih@upmc.edu
연구 장소
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- UPMC Shadyside Hospital
-
수석 연구원:
- Jacques E. Chelly, MD, PhD, MBA
-
연락하다:
- Heather Margonari,, DNP, FNP-BC
- 전화번호: 412-623-1914
- 이메일: margonarih@upmc.edu
-
연락하다:
- Sarah Warner
- 이메일: warners3@upmc.edu
-
Pittsburgh, Pennsylvania, 미국, 15237
- UPMC Passavant Hospital
-
수석 연구원:
- Jacques E. Chelly, MD, PhD, MBA
-
Pittsburgh, Pennsylvania, 미국, 15146
- UPMC East Hospital
-
수석 연구원:
- Jacques E. Chelly, MD, PhD, MBA
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- >18 years of age
- Scheduled for elective primary unilateral TKA
Exclusion Criteria:
- Children (<18 yr.)
- Pregnant women
- Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
- Severe chronic pain condition that requires daily preoperative opioid dependence
- Other concomitant surgery being performed in addition to TKA
- Patients undergoing bilateral TKA
- Patients undergoing knee replacement revision
- Patients with limited mobility (in a wheelchair or requiring a walker)
- Patients who are not returning home after surgery
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: NEUROCUPLE™ Group
This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 7 days following their TKA surgery. |
nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year. The patch will be worn for 7-days Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications |
|
가짜 비교기: Sham Group
This arm of subjects will receive the placebo (non-active, sham) patch to wear for 7 days following their TKA surgery. |
Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications Non-active placebo patch visually identical to NEUROCUPLE™ worn for 7 days following total knee arthroplasty. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Opioid Consumption
기간: 0- 24 hours post-surgery
|
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP). MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, while higher MME values suggest increased opioid use and potentially greater pain or slower recovery. |
0- 24 hours post-surgery
|
|
Pain at Rest Using Numerical Rating Scale (NRS)
기간: 0-24 hours post-surgery
|
Pain at rest during the first 24 hours after surgery will be assessed using a Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain) and compared between the NEUROCUPLE™ patch group and the placebo patch group. Higher scores indicate worse pain |
0-24 hours post-surgery
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pain Scores Using Numerical Rating Scale (NRS) at Rest and during Movement
기간: Post-operative at Day 2 and Day 7
|
Pain will be assessed using a Numerical Rating Scale (0 = no pain, 10 = worst pain) at rest and during movement on postoperative Days 2 and 7. Higher scores indicate worse pain. |
Post-operative at Day 2 and Day 7
|
|
Patient Satisfaction
기간: at Post-operative Day 7
|
Patient satisfaction with recovery and device use will be assessed on postoperative Day 7 using standardized questionnaires. Scores range from 0 to 10, where 0 indicates the lowest level of satisfaction and 10 indicates the highest. |
at Post-operative Day 7
|
|
Opioid Consumption
기간: Post-Operative Day 0- Day 7
|
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), will be recorded over the 7-day postoperative period. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and the state Prescription Drug Monitoring Program (PDMP) when applicable. MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, whereas higher MME values suggest increased opioid use and potentially greater pain or slower recovery. |
Post-Operative Day 0- Day 7
|
|
Postoperative Adverse Events and Device-Related Side Effects
기간: Postoperative Days 0-7
|
The incidence of postoperative adverse events, including any events determined to be related to the study device, will be recorded and compared between the treatment groups during the 7-day postoperative period. Lower incidence rates indicate fewer complications and a more favorable safety profile, whereas higher incidence rates suggest increased complications, potential device-related issues, or a less favorable safety profile. |
Postoperative Days 0-7
|
|
Incidence of postoperative nausea and/or vomiting (yes/no)
기간: Postoperative Days 0-7
|
Incidence and severity of postoperative nausea and vomiting will be recorded over the 7-day postoperative period as (yes/no) and compared between groups. |
Postoperative Days 0-7
|
|
Postoperative Length of Stay
기간: From the date of surgery until hospital discharge (within the 7-day study period)
|
Length of hospital stay, defined as the number of days from the date of surgery to the date of hospital discharge, will be recorded and compared between groups. Lower length of stay values indicate faster recovery, fewer complications, and earlier readiness for discharge. Higher length of stay values suggest slower recovery, increased complications, or higher postoperative symptom burden. |
From the date of surgery until hospital discharge (within the 7-day study period)
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Jacques E. Chelly, MD, PhD, MBA, University of Pittsburgh / UPMC
- 연구 책임자: Alisha Maslanka, BS, CCRC, University of Pittsburgh / UPMC
- 연구 책임자: Heather Margonari,, University of Pittsburgh / UPMC
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- STUDY25120065
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .